前列舒丸联合多沙唑嗪治疗前列腺增生症的临床研究

Clinical study on Qianqianshu Pills combined with doxazosin in treatment of prostatic hyperplasia

目的研究前列舒丸联合甲磺酸多沙唑嗪片治疗前列腺增生的临床疗效。方法选取2018年7月-2019年7月来郑州大学第一附属医院治疗的100例前列腺增生症患者,将所有患者随机分为对照组和治疗组,每组各50例。对照组患者口服甲磺酸多沙唑嗪片,1mg/次,1次/d;治疗组在对照组治疗的基础上口服前列舒丸,1粒/次,3次/d。两组患者持续治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者国际前列腺症状评分(IPSS)、生活质量(QOL)评分、前列腺体积(PV)、膀胱残余尿量(RV)、最大尿流率(Qmax)和血清炎性因子水平。结果治疗后,对照组、治疗组的总有效率分别为86.00%、98.00%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组IPSS评分、QOL评分均显著降低(P<0.05);且治疗组IPSS评分、QOL评分降低较多(P<0.05)。治疗后,两组RV、PV水平均显著降低,Qmax水平显著升高(P<0.05);且治疗组RV、PV水平显著低于对照组,Qmax水平显著高于对照组(P<0.05)。治疗后,两组患者IL-6、TNF-α水平均明显降低(P<0.05);且治疗组IL-6、TNF-α水平降低较多(P<0.05)。结论前列舒丸联合甲磺酸多沙唑嗪片治疗前列腺增生症具有较好的临床疗效,可改善临床症状,降低血清炎性因子水平,值得在临床上推广应用。

Objective To study the effect of Qianqianshu Pills combined with Doxazosin Mesylate Tablets in treatment of prostatic hyperplasia. Methods Patients(100 cases) with prostatic hyperplasia in First Affiliated Hospital of Zhengzhou University from July 2018 to July 2019 were randomly divided into control(50 cases) and treatment(50 cases) groups. Patients in the control group were po administered with Doxazosin Mesylate Tablets, 1 mg/time, once daily. Patients in the treatment group were po administered with Qianqianshu Pills on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the international prostate symptom score(IPSS) and quality of life score(QOL) scores, prostate volume(PV), bladder residual urine volume(RV), maximum urine flow rate(Qmax) and serum inflammatory factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.00% and 98.00%, respectively, and there was difference between two groups(P<0.05). After treatment, IPSS and QOL scores in two groups were significantly decreased(P<0.05). And IPSS and QOL scores in the treatment group were significantly lower than those in the control group(P<0.05). After treatment, RV and PV in two groups were significantly decreased, but Qmax in two groups were significantly increased(P<0.05). And RV and PV in the treatment group were significantly lower than those in the control group, but Qmax in the treatment group were significantly higher than those in the control group(P<0.05). After treatment, the levels of IL-6 and TNF-α in two groups were significantly decreased(P<0.05). And the levels of IL-6 and TNF-α in the treatment group were significantly lower than those in the control group(P<0.05). Conclusion Qianqianshu Pills combined with Doxazosin Mesylate Tablets has clinical curative effect in treatment of prostatic hyperplasia, can improve clinical symptoms and reduce the levels of serum inflammatory factors, which has a certain clinical application value.